Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
22
EDIT Quote, Financials, Valuation and Earnings
Last price:
$1.26
Seasonality move
:
-11.28%
Day range:
$1.28 - $1.38
52-week range:
$1.28 - $11.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.74x
P/B ratio:
0.62x
Volume:
4.2M
Avg. volume:
2.9M
1-year change:
-87.17%
Market cap:
$108.1M
Revenue:
$78.1M
EPS (TTM):
-$2.56
Analysts' Opinion
-
Consensus RatingEditas Medicine has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Editas Medicine has an estimated upside of 179.9% from its current price of $1.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.31.
Fair Value
-
According to the consensus of 0 analysts, Editas Medicine has 179.9% upside to fair value with a price target of -- per share.
EDIT vs. S&P 500
-
Over the past 5 trading days, Editas Medicine has underperformed the S&P 500 by -7.18% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Editas Medicine does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Editas Medicine revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Editas Medicine reported revenues of $61K.
Earnings Growth
-
Editas Medicine has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Editas Medicine reported earnings per share of -$0.75.
Enterprise value:
-157M
EV / Invested capital:
-0.89x
Price / LTM sales:
1.74x
EV / EBIT:
--
EV / Revenue:
-2.54x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.82x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-48.82%
Net Income Margin (TTM):
-340.96%
Return On Equity:
-74.59%
Return On Invested Capital:
-74.59%
Operating Margin:
-107649.18%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $25.6M | $24.6M | $61.8M | $5.3M | $61K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$204.1M | -$208.7M | -$228.5M | -$50.2M | -$65.7M | |
| EBITDA | -$197.8M | -$202.5M | -$222.6M | -$48.6M | -$64.1M | |
| Diluted EPS | -$2.94 | -$2.70 | -$2.56 | -$0.55 | -$0.75 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $506.8M | $567.6M | $426.6M | $358.6M | $271.1M | |
| Total Assets | $597.2M | $717M | $531M | $504.7M | $327.6M | |
| Current Liabilities | $54.8M | $50.9M | $42.3M | $58.6M | $72.4M | |
| Total Liabilities | $156M | $130.2M | $116.3M | $144.2M | $151.9M | |
| Total Equity | $441.2M | $586.8M | $414.7M | $360.5M | $175.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$169.7M | -$152.2M | -$181.8M | -$35.5M | -$52.6M | |
| Cash From Investing | $118.8M | -$94.1M | $194M | -$102.8M | $84M | |
| Cash From Financing | $1.7M | $118.1M | $1M | -- | -- | |
| Free Cash Flow | -$176M | -$156.2M | -$191.4M | -$35.7M | -$55.5M | |
EDIT
Sector
Market Cap
$108.1M
$43.9M
Price % of 52-Week High
11.31%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-87.17%
-29.11%
Beta (5-Year)
1.864
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.54
200-day SMA
Sell
Level
$4.58
Bollinger Bands (100)
Sell
Level
2.37 - 4.05
Chaikin Money Flow
Sell
Level
-150.6M
20-day SMA
Sell
Level
$1.92
Relative Strength Index (RSI14)
Sell
Level
23.89
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-97.235
50-day SMA
Sell
Level
$2.60
MACD (12, 26)
Sell
Level
-0.36
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Sell
Level
-57.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.4362)
Sell
CA Score
(Annual)
Level (-0.9905)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.7121)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Stock Forecast FAQ
In the current month, EDIT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EDIT average analyst price target in the past 3 months is --.
-
Where Will Editas Medicine Stock Be In 1 Year?
According to analysts, the consensus estimate is that Editas Medicine share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Editas Medicine?
Analysts are divided on their view about Editas Medicine share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Editas Medicine is a Sell and believe this share price will drop from its current level to --.
-
What Is Editas Medicine's Price Target?
The price target for Editas Medicine over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EDIT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Editas Medicine is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EDIT?
You can purchase shares of Editas Medicine via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Editas Medicine shares.
-
What Is The Editas Medicine Share Price Today?
Editas Medicine was last trading at $1.26 per share. This represents the most recent stock quote for Editas Medicine. Yesterday, Editas Medicine closed at $1.31 per share.
-
How To Buy Editas Medicine Stock Online?
In order to purchase Editas Medicine stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
